Drugs / Pembrolizumab/Quavonlimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04626479 | Dec 2020 → Aug 2026 | renal cell carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pembrolizumab/Quavonlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04626479 ↗ |